Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Getting a diagnosis

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background The epsilon4 allele of the gene encoding apolipoprotein E (APOE) is strongly associated with Alzheimer's disease, but its value in the diagnosis remains uncertain. Methods We reviewed clinical diagnoses and diagnoses obtained at autopsy in 2188 patients referred to 1 of 26 Alzheimer's disease centers for evaluation of dementia. The sensitivity and specificity of the clinical diagnosis or the presence of an APOE epsilon4 allele were calculated, with pathologically confirmed Alzheimer's disease used as the standard. The added value of the APOE genotype was estimated with pretest and post-test probabilities from multivariate analyses to generate receiver-operating-characteristic curves plotting sensitivity against the false positive rate. Results Of the 2188 patients, 1833 were given a clinical diagnosis of Alzheimer's disease, and the diagnosis was confirmed pathologically in 1770 patients at autopsy. Sixty-two percent of patients with clinically diagnosed Alzheimer's disease, as compared with 65 percent of those with pathologically confirmed Alzheimer's disease, had at least one APOE epsilon4 allele. The sensitivity of the clinical diagnosis was 93 percent, and the specificity was 55 percent, whereas the sensitivity and specificity of the APOE epsilon4 allele were 65 and 68 percent, respectively. The addition of information about the APOE genotype increased the overall specificity to 84 percent in patients who met the clinical criteria for Alzheimer's disease, although the sensitivity decreased. The improvement in specificity remained statistically significant in the multivariate analysis after adjustment for differences in age, clinical diagnosis, sex, and center. Conclusions APOE genotyping does not provide sufficient sensitivity or specificity to be used alone as a diagnostic test for Alzheimer's disease, but when used in combination with clinical criteria, it improves the specificity of the diagnosis.

What this study adds

Evidence grade: Low

The record lists 2,188 participants. Adding APOE genotype information to a clinical diagnosis did not clearly improve the accuracy of diagnosing Alzheimer's disease in this study. The clinical diagnosis alone had high sensitivity but low specificity, and the APOE epsilon4 allele by itself was not accurate enough to confirm or rule out the disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Mayeux, R., Saunders, A. M., Shea, S., Mirra, S., Evans, D., Roses, A. D., et al. (1998). Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. The New England journal of medicine. https://doi.org/10.1056/nejm199802193380804

Vancouver

Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. The New England journal of medicine. 1998. doi:10.1056/nejm199802193380804. PMID: 9468467.

BibTeX

@article{mayeux1998-9468467,
  author  = {Mayeux, R. and Saunders, A. M. and Shea, S. and Mirra, S. and Evans, D. and Roses, A. D. and Hyman, B. T. and Crain, B. and others},
  title   = {{Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {1998},
  doi     = {10.1056/nejm199802193380804},
  pmid    = {9468467},
  url     = {https://doi.org/10.1056/nejm199802193380804}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Adding APOE genotype information to a clinical diagnosis did not clearly improve the accuracy of diagnosing Alzheimer's disease in this study. The clinical diagnosis alone had high sensitivity but low specificity, and the APOE epsilon4 allele by itself was not accurate enough to confirm or rule out the disease.

Study details

How this study scored 61/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 3 of 5; Impact for its field and year 5 of 6; Cited by studies here 4 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 3 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 61 of 100.61 of 100 points earned39 not earned

Published in a top-tier journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (The New England journal of medicine)
Journal's citation record 4 / 4 New England Journal of Medicine: journal h-index 1,505 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 1998 — older than 20 years, still counted
Sample size 3 / 4 2,188 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 552 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 18.4 citations a year over 30 year(s) since 1998
Impact for its field and year 5 / 6 Cited 32.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 44 other studies in this library
Still being cited 2 / 4 Cited 20 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Creighton H. Phelps: h-index 26 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 9 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 9468467)
Free to read 0 / 2 Behind a paywall — scores zero
Total 61 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.

Later studies that cite this one

44 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Getting a diagnosis from nearby years

Also tagged “precursor”

1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →